nav-left cat-right
cat-right

Michael J. Fox Foundation Awards $4.4 Million for ...

NEW YORK, Dec. 18 /PRNewswire-USNewswire/ — The Michael J. Fox Foundation has awarded $4.4 million to jump-start the development of a new class of symptomatic Parkinson’s disease drugs targeting glutamate receptor mGluR4. The funding was awarded to a multidisciplinary team of researchers led by Jeffrey Conn, PhD, of Vanderbilt University under the Foundation’s LEAPS (Linked Efforts to Accelerate...

European research agenda for pathogenomics adopted

Network of Excellence EuroPathoGenomics has undergone its first review Researchers have long been fascinated by microorganisms, as they can be both useful inhabitants of the body and dangerous pathogens. In 2005, to better understand this dual role, 37 researcher teams from 13 different European countries founded the Network of Excellence EuroPathoGenomics (NoE EPG). The members have now adopted a common Research Agenda for...

CLC bio joins $2.5M research project on HIV, bird ...

Aarhus Denmark, April 30, 2007 — CLC bio, the IT University of Copenhagen, and the Department of Molecular Biology at the interdisciplinary nano science centre (iNANO) of University of Aarhus are proud to announce that the Danish Council for Strategic Research has approved to fund the ambitious and ground-breaking research project PC Mini Grids for Prediction of Viral RNA Structure and Evolution. Professor at the...

Giving worms a taste of their own medicine

The humble nematode worm could prove invaluable in screening new compounds for active drugs, new research published today suggests. Soil-dwelling nematodes have a programmed avoidance response to harmful chemicals, which they detect through nerves exposed to their environment. Scientists led by the Wellcome Trust Sanger Institute have genetically modified the worm C. elegans to make human proteins called receptors in these...

Dow AgroSciences Extends Research Collaboration wi...

Locus Pharmaceuticals, Inc., a computationally-based drug design and development company, announced today the continuation of its multi-stage research collaboration with Dow AgroSciences LLC, a subsidiary of The Dow Chemical Company (NYSE:DOW), focused on agrochemicals and biotechnology innovation. The collaboration involves the application of Locus’ proprietary computational technologies to design and develop novel...

Evotec Successfully Completes Single Ascending Dos...

3 February 2006, Hamburg, Germany | Oxford, UK – Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced the successful completion of the single ascending dose component of the Phase I clinical study with EVT 101, a subtype-specific NMDA receptor antagonist for the treatment of Alzheimer’s disease. The study in 48 young healthy subjects of whom 36 received EVT 101 showed that EVT 101 was well...
Page 30 of 34« First...1020...2829303132...Last »